CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Evaluate wide market index fund performance against the SP 500 in retirement planning, emphasizing return consistency and fee impact.
28,313 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A major cold storage leader caught the eye of a notable investor, who disclosed a fresh stake worth $19 million. This...
The IMF says the U.S. economy remains robust, but mounting deficits and tariff policy threaten long-term balance. Thi...
A high-stakes moment at Davos shifted sentiment in crypto markets. Michael Saylor announced a record BTC purchase, wh...
Crescent Capital BDC offers a high-yield opportunity along with risks linked to debt investments. This guide breaks d...
SpaceX’s S-1 filing puts Elon Musk’s Mars ambitions under the public lens, inviting investors to weigh a multi-billio...
You don’t have to run every deal to build real estate wealth. This guide shows how to fire yourself still scale—deleg...
A high-profile insider sale by AeroVironment's CEO has investors asking what it means for the stock. This guide break...
SpaceX may be the headline grabber, but buying on day one isn’t a slam-dunk. This guide gives you three essential que...
An executive’s $3.6 million share sale can spark questions for investors. This comprehensive guide explains what the ...
As job cuts persist in early 2026, employers cite AI adoption to explain restructuring. The trend underscores why wor...
As the first federal reserve inflation forecast for March lands, markets wrestle with what it signals for rate paths ...